On the one hand, when the OS analysis was restricted to EGFR wild-type NSCLC patients who received standard first-line chemotherapy, a clear benefit in OS was observed in favor of individuals without liver involvement compared to those patients with liver disease [23 months (95% CI 13.1–32.9) vs. 13 months (95% CI 8.1–17.9), respectively; p = 0.001]. This evidence concerns the gene EGFR and liver disorder.